Laropiprant
| |
| Laropiprant
| |
| Systematic (IUPAC) name | |
| (-)-[(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)- 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C21H19ClFNO4S |
| Mol. mass | 435.90 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Laropiprant | |
|
Articles | |
|---|---|
|
Most recent articles on Laropiprant Most cited articles on Laropiprant | |
|
Media | |
|
Powerpoint slides on Laropiprant | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Laropiprant at Clinical Trials.gov Clinical Trials on Laropiprant at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Laropiprant
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Laropiprant Discussion groups on Laropiprant Patient Handouts on Laropiprant Directions to Hospitals Treating Laropiprant Risk calculators and risk factors for Laropiprant
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Laropiprant | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laropiprant (pINN; codenamed MK-0524A) is an investigational treatment for hypercholesterolemia. It is a prostanoid DP1 receptor antagonist. It will be marketed by Merck & Co. as a combination with niacin and will be sold under the tradenames Cordaptive and Tredaptive.
In October 2008, Merck expanded the THRIVE Trial from 20,000 to 25,000 patients in order to expedite a second bid for FDA approval of its experimental cholesterol drug, MK-0524A. MK-0524A is a combination of niacin and laropiprant, which is aimed at limiting facial flushing associated with niacin. In April 2008 the FDA decided to withhold approval for the experimental drug, deciding to wait until the results of the THRIVE Trial could be analyzed.[1]
Lipid modifying agents (C10) | |
|---|---|
| Statins | Atorvastatin • Cerivastatin‡ • Fluvastatin • Lovastatin • Mevastatin • Pitavastatin • Pravastatin • Rosuvastatin • Simvastatin |
| Fibrates | Clofibrate‡ • Bezafibrate • Aluminium clofibrate • Gemfibrozil • Fenofibrate • Simfibrate • Ronifibrate • Ciprofibrate • Etofibrate • Clofibride |
| Bile acid sequestrants | Colestyramine • Colestipol • Colestilan • Colextran • Colesevelam |
| Niacin and derivatives | Niceritrol • Niacin • Nicofuranose• Aluminium nicotinate• Nicotinyl alcohol • Acipimox |
| CETP inhibitors | Anacetrapib† • Torcetrapib§ |
| Combinations | Niacin/lovastatin • Niacin/simvastatin • Ezetimibe/simvastatin |
| Other | Dextrothyroxine • Probucol • Tiadenol • Benfluorex • Meglutol • Omega-3-triglycerides • Magnesium pyridoxal 5-phosphate glutamate • Policosanol • Ezetimibe • Laropiprant • Lapaquistat§ |
| †Undergoing clinical trials. ‡Withdrawn from market. §Development terminated. | |
Cite error:
<ref> tags exist, but no <references/> tag was found
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
